Efficacy of ILC depletion by anti‐CD90.2 (YTS) injection was confirmed by a reduction of ILC in the colon as compared with control mice and saline or isotype injected chronic DSS colitis mice (0.99% vs 29.35%, 25.70%, and 29.85% of CD45+ cells, P = .002, P = .029, and P = .018, respectively; Figure 4A and S4A,B). The gene discussed is PTPRC; the disease is colitis.